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http://dx.doi.org/10.1016/j.ccell.2015.09.005SUMMARYHuman epidermal growth factor receptor 2 (HER2) is upregulated in a subset of human breast cancers. How-
ever, the cancer cells often quickly develop an adaptive response to HER2 kinase inhibitors. We found that an
epigenetic pathway involving MLL2 is crucial for growth of HER2+ cells and MLL2 reduces sensitivity of the
cancer cells to a HER2 inhibitor, lapatinib. Lapatinib-induced FOXO transcription factors, normally tumor-
suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating
epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib. An epigenetic inhibitor suppress-
ing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc
axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.INTRODUCTION
The gene for human epidermal growth factor receptor 2 (HER2 or
ERBB2) is often amplified or overexpressed in a subgroup of
breast cancers and is associated with poor prognosis (Slamon
et al., 1987). The HER2/EGFR (human epidermal growth factor
receptor 2/epidermal growth factor receptor) complex can
activate a downstream cascade of protein kinases including
phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT),
promoting tumorigenesis by increasing cell proliferation and
survival (Schlessinger, 2000). Trastuzumab (Herceptin), a mono-
clonal antibody against the ectodomain of HER2, and the small
molecule HER2 tyrosine kinase inhibitor lapatinib (Tykerb) are
approved for treating HER2-overexpressing breast cancer (Mo-
lina et al., 2001; Wood et al., 2004). Whereas trastuzumab (Her-
ceptin) resistance is associated with increased signaling fromSignificance
Whereas the HER2/PI3K/AKT pathway is frequently mutated in
itors of this pathway such as lapatinib yield only limited succe
that theMLL2/FOXO/c-Myc axis was activated by lapatinib, red
an intrinsic adaptation pathway comprising the normally mutu
lated by multiple epigenetic regulators, but also highlight sev
improve therapy. As proof of principle, a BRD4 inhibitor and lap
in vitro and in vivo, at least partly, by targeting the MLL2/FOX
472 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.the insulin-like growth factor-I receptor (IGF-IR) or a PTENmuta-
tion (Lu et al., 2001; Nagata et al., 2004), lapatinib exerts its anti-
tumor activity in a PTEN-independent manner (Xia et al., 2007),
and thus remains useful for treating certain patients with resis-
tance to trastuzumab. Adaptive response to lapatinib or PI3K/
AKT inhibitor can develop via several means including increased
estrogen receptor signaling and upregulation of pro-survival fac-
tors and receptor tyrosine kinases (such as HER3 and IGF-1R)
(Chandarlapaty et al., 2011; Garrett et al., 2011; Muranen et al.,
2012; Xia et al., 2006). However, precise mechanisms underlying
the epigenetic response to lapatinib in terms of controlling sensi-
tivity or resistance are poorly understood. As such, understand-
ing whether/how sensitivity to lapatinib is epigenetically or tran-
scriptionally controlled in HER2+ cancer and developing more
effective treatment modalities based on these mechanisms are
highly desirable.a wide range of cancers, thus driving tumorigenesis, inhib-
ss, because the cancer cells often adapt quickly. We found
ucing sensitivity to the drug. These findings not only uncover
ally antagonizing players, FOXOs and c-Myc, that are regu-
eral key components in the pathway for future targeting to
atinib synergistically suppressed HER2+ breast cancer cells
O/c-Myc axis.
The HER2 pathway can activate various downstream effec-
tors including PI3K and AKT, which phosphorylate FOXO tran-
scription factors and result in their subsequent sequestration in
the cytoplasm, suppressing their transcriptional activity (Greer
and Brunet, 2005). FOXOs are known as tumor suppressors
because they upregulate cyclin-dependent kinase inhibitors
(CDKIs) p21Cip1 and p27Kip1 and pro-apoptotic proteins such
as Bim (Eijkelenboom and Burgering, 2013; Greer and Brunet,
2005). Inhibiting the kinase activity of HER2 or PI3K/AKT by
cognate kinase inhibitors leads to reduction in phosphorylation
of FOXOs, and thus triggers their translocation into the nucleus
and upregulates transcription of their target genes (Gilley et al.,
2003). An early response to treatment of breast cancer cells
with PI3K/AKT inhibitors or lapatinib is enhanced translocation
of FOXOs into the nucleus, leading to upregulation of several
receptor tyrosine kinases (RTKs) and resistance to the inhibi-
tors (Chandarlapaty et al., 2011; Garrett et al., 2011; Muranen
et al., 2012).
Targeting epigenetically regulated pathways in cancer cells is
a rapidly emerging approach for therapy (Yoo and Jones, 2006).
Epigenetic landscapes are commonly altered in cancer cells,
and the promise of therapeutically targeting such pathways in
breast cancers has been limited due to a poor understanding
of the epigenetic regulatory mechanisms in response to the
HER2/AKT inhibitors. Mixed lineage leukemia (MLL) proteins
contain a highly conserved SET domain that catalyzes histone
3 lysine 4 (H3K4) trimethylation (Krivtsov and Armstrong, 2007),
which is involved in the upregulation of gene transcription (Gu
et al., 1992). In humans, there are several proteins in the MLL
family such as MLL (KMT2A), MLL2 (KMT2D), MLL3 (KMT2C),
and MLL4 (KMT2B), and MLL and MLL2 associate with co-fac-
tors WDR5, RBBP5, and ASH2L. However, it is unclear whether
any member of the MLL family is involved in regulating sensitivity
to HER2 inhibitors. Thus it is important to investigate whether
epigenetic regulation cross-talks with the HER2/AKT pathway
to regulate breast cancer cell signaling and sensitivity to HER2/
AKT inhibitors. In our current study, we investigated the potential
crosstalk between epigenetic pathways and the sensitivity to la-
patinib in HER2+ breast cancers.
RESULTS
shRNA-Based Screening Identified Multiple
Components in MLL Complexes that Are Crucial for
Growth of BT474 Breast Cancer Cells
To determine the potential impact of the epigenetic modulators
on regulating sensitivity/resistance of HER2+ breast cancer
cells to targeted drugs, we chose a two-tier approach—first
identifying the epigenetic regulators that are crucial for cancer
cell growth, followed by examining the potential role of the
identified epigenetic modulators in regulating sensitivity to a
HER2-inhibition drug such as lapatinib. To this end, first we
assembled an shRNA library targeting epigenetic regulators
including multiple histone methyl- or acetyl-transferases. Four
to six distinct shRNAs targeting each gene product were pack-
aged in recombinant lentiviruses and were transduced into
HER2+ BT474 cells in 96-well plates (Figure 1A). We monitored
growth of the resulting puromycin-resistant cells and found that
knockdown of multiple epigenetic regulators led to reducedCgrowth of the BT474 cells (Table S1). Notably, knocking down
various components of the MLL (MLL and MLL2 share multiple
components, or COMPASS), including WDR5, ASH2L, and
RBBP5 (Issaeva et al., 2007; Smith et al., 2011), decreased
the growth of BT474 cells (Figure 1B). In contrast, shRNAs tar-
geting MLL3 and MLL4, two homologous methyltransferases
(Figure S1A), failed to repress cell growth in either the original
screen or in verified knockdown experiments (Table S1 and
data not shown).
We further verified the impact of knockdown of MLL, MLL2,
and their co-factors on cell growth through dedicated shRNA ex-
periments. To do this, we transduced control or MLL or MLL2
shRNA-expressing recombinant viruses to BT474 cells and
found that knockdown of either MLL or MLL2 reduced the cell
growth (Figures 1C and 1D). We also knocked down other com-
ponents of MLL2 complex including WDR5 and ASH2L, and
BPTF, a reader of H3K4 trimethylated by MLLs, as well as his-
tone acetyltransferase GCN5, and found that their knockdown
resulted in reduction of cell number (Figure S1B). These results
suggest that MLL and MLL2 and their related factors play an
important role in growth of HER2 + BT474 cells.
MLL andMLL2 Regulate Distinct Sets of Genes in HER2+
Breast Cancer Cells
Recent work indicates that Bcl2 family proteins play a crucial role
in tumorigenesis and chemoresistance of breast cancer cells
and c-Myc is important in regulating survival and proliferation
of breast cancer cells (Dawson et al., 2010; Lang et al., 2011;
Liao and Dickson, 2000; Vaillant et al., 2013). As such, we deter-
mined whether MLL and MLL2 are crucial for their expression.
We found that shRNA-mediated knockdown of MLL decreased
the expression of Bclxl but not Bcl2 or c-Myc (Figure 1E). In
contrast, MLL2 knockdown had no effect on Bclxl expression,
but decreased the expression of Bcl2 and c-Myc (Figure 1F).
Collectively, these results indicate that MLL2, but not MLL, is
crucial for expression of c-Myc and Bcl2 in the BT474 breast
cancer cells.
HER2 Inhibitor Induces Expression of c-Myc and
Maintains the HER2+ Breast Cancer Cells at a Steady
State
Activation of Ras/HER2/PI3K signaling pathways alters the
expression of c-Myc via affecting transcription, mRNA transla-
tion, and protein stability (Galmozzi et al., 2004; Sears et al.,
2000; Zhu et al., 2008). Bcl2 is also upregulated in the HER2+
breast cancer cells treated with lapatinib (Xia et al., 2006), but
the impact of lapatinib on c-Myc was not determined. We sought
to determinewhetherMLL2-regulated c-Myc is influenced by the
highly activated HER2 signaling pathway, before we set out to
understand MLL2-mediated regulation of c-Myc expression.
We found that lapatinib induced Bcl2 mRNA levels in BT474
cells as expected (Figure 2A). Notably, lapatinib also increased
mRNA level of c-Myc (Figure 2A). FOXO transcription factors
are phosphorylated by AKT and inhibition of AKT-mediated
phosphorylation of FOXOs activates FOXOs by increasing their
localization in the nucleus. We found that lapatinib treatment
increased c-Myc mRNA and FOXO1 mRNA after 8 hr of
treatment, an effect lasting for several days after daily treatment
(Figures S2A–S2C).ancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 473
Figure 1. shRNA-Based Screening Identified Multiple Components in MLL Complexes that Are Crucial for Growth of BT474 Breast Cancer
Cells and Expression of c-Myc and BCL2
(A) A schema for screening shRNA library in BT474 cells.
(B) Summary of the impact of knockdown of each of the MLL or MLL2 complex components on cell growth in the screening.
(C and D) Impact of knockdown of MLL (C) or MLL2 (D) on cell growth in large dishes of BT474 cells.
(E and F) Impact of knockdown of MLL (E) or MLL2 (F) on expression of MLL or MLL2 and Bclxl, Bcl2 and c-Myc using qRT-PCR assay. Error bars indicate ±SD.
See also Figure S1 and Table S1.Lapatinib treatment decreased c-Myc protein level on day 1 of
treatment (data not shown). However, daily treatment gradually
increased the protein level of c-Myc (Figure 2B) and consistently
reduced phosphorylation of AKT and increased protein level of
HER3 (Figure 2B), a protein known to be upregulated by lapatinib
(Chandarlapaty et al., 2011; Garrett et al., 2011; Lu et al., 2001).
However, lapatinib increased expression of a pro-apototic pro-
tein, Bim (Figure 2B). Moreover, lapatinib also reduced phos-
phorylation of FOXO1 (Figure 2B), whose phosphorylation by
active AKT leads its sequestration in the cytoplasm and inac-
tivation (Gilley et al., 2003), but increased the total FOXO1
(Figure 2B).
If lapatinib induces c-Myc expression via suppressing AKT-
mediated FOXO phosphorylation, then, treating BT474 cells
with an AKT inhibitor should also lead to increased expression
of c-Myc. Indeed, treatment of BT474 cells with an AKT inhibitor,474 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.MK2206 (referred to as AKTi hereafter), increased the level of
c-Myc at RNA and protein level, but reduced phosphorylation
of AKT and FOXO1 (Figure S2D and data not shown). Altogether,
these results suggest that lapatinib and AKTi led to suppression
of the HER2/PI3K/AKT pathway, reducing AKT activity and con-
sequently upregulating c-Myc and FOXO1.
We found that the cell death occurred rapidly after lapatinib
treatment for the first 3 days and thereafter the number of the
dead cells decreased (Figure 2C). However, while control cells
continued to grow, even at day 6 following the treatment, lapati-
nib did not substantially reduce the number of the viable cells as
compared to the cell number at the start of the lapatinib treat-
ment (Figure 2D). Rather, during this period, lapatinib led to an
overall steady state in viable cell number. Careful monitoring of
cell cycle showed that lapatinib reduced bromodeoxyuridine up-
take at S-phase of the cancer cells from 18.8%of cells to 2.32%,
Figure 2. Effect of Lapatinib on Expression of c-Myc and Bcl2, Both Upregulated by MLL2 and HER2 Inhibitor Lapatinib
(A) BT474 cells were treated daily with lapatinib (200 nM) for 3 days, followed by additional 18 hr, prior to qRT-PCR analysis for c-Myc and Bcl2.
(B) BT474 cells were treated daily with DMSO or lapatinib (200 nM) for the indicated days, collected 18 hr after the last treatment for western blot analysis with the
indicated antibodies.
(C and D) In experiments parallel to (B), the dead cells (C) and viable cells (D) were counted on the indicated days.
(E and F)MDA-MB-361, were treated with 50 nMAKTi, MK2206, for 4 days; collected 18 hr after the last treatment for analysis for expression of c-Myc and Bcl2 at
the mRNA level using qRT-PCR (E) or protein levels of various proteins using western blotting (F). Error bars indicate ±SD.
See also Figure S2.a lower yet still detectable level (Figure S2E). These findings sug-
gest that lapatinib-treated cells reached equilibrium of cell divi-
sion and death, displaying loss of sensitivity or resistance to
treatment by lapatinib.
AKT Inhibitor Induces c-Myc Expression in Breast
Cancer Cells with Enhanced PI3K/AKT Signaling
The observation that lapatinib induces c-Myc is paradoxical
because inhibition of a key tumor-driving HER2/AKT pathway in-
duces a potent oncogene c-Myc, and c-Myc expression is usu-
ally inversely related to cell growth (Spencer and Groudine,
1991). Thus, we further explored whether lapatinib or AKTi-
induced c-Myc expression we observed is unique to BT474 cells
or also applies to other HER2/PI3K-activated breast cancer cell
lines. Many HER2+ breast cancer cell lines also harbor constitu-
tively active mutations in PIK3CA that encodes a downstream
effector of HER2 signaling; perhaps further increasing the
strength of HER2 signaling.
When PI3K is hyper-activated or constitutively activated due
to an active mutation, lapatinib is no longer able to inhibit
PI3K/AKT signaling, because constitutively activated PI3K canCactivate downstream targets (including AKTs) regardless of
the active status of HER2 (Eichhorn et al., 2008). However, the
inhibitor of AKTs should remain capable of inducing c-Myc
expression.
Indeed, treatment of MDA-MB-361 cells, which harbor
PIK3CA E545K mutation, with AKTi, but not lapatinib (data not
shown), induced expression of c-Myc (Figures 2E and 2F). More-
over, AKTi inhibited phosphorylation of AKT and FOXO1 pre-
cisely as lapatinib inhibited this in BT474 cells (Figure S2D).
Consistently, treatment of MCF-HER2 cells with AKTi also led
to induction of c-Myc expression (Figures S2F and S2G).
To extend our findings to an even greater number of cell lines,
we examined whether lapatinib influences expression of c-Myc
in another HER2+ (amplified) human breast cell line, UACC812
(Wang et al., 2011). We found that lapatinib also increased
expression of c-Myc mRNA and protein levels in UACC812 cells
(Figures S2H and S2I). Collectively, these results indicate that
inhibition of the HER2/AKT pathway in multiple breast cancer
cell lines induces expression of c-Myc. Because lapatinib is
approved for treating breast cancer, we focused on examining
the impact of lapatinib on HER2+ cancer cells.ancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 475
Figure 3. The Crucial Role of Lapatinib-Induced c-Myc in Reducing the Sensitivity of the Breast Cancer Cells to Lapatinib
(A) The doxycycline-inducible c-Myc shRNA lentivirus-transduced BT474 cells were treated with doxycycline (200 ng/ml) for 2 days, followed by treatment with
various concentrations of lapatinib for 6 days, collected 18 hr after the last treatment, prior to detection of the protein level of c-Myc by western blotting.
(B) The viable cells treated as described in (A) were counted.
(C and D) BT474 cells were treated with lapatinib (200 nM) and/or IBET (500 nM) for 4 days prior to analysis with qRT-PCR for the mRNA level (C) or with western
blotting for various proteins with the indicated antibodies (D).
(E) BT474 cells were transduced with either control vector or human c-Myc-expressing lentiviruses, followed by puromycin selection and western blot analysis for
c-Myc expression.
(F) Western blot analysis for the c-Myc expression in the vector control cells or c-Myc-transduced cells that were treated with lapatinib (50 nM) andwith or without
IBET (500 nM).
(G) The control and c-Myc-transduced cells in the presence of lapatinib (50 nM) were treated with either DMSO or IBET (500 nM) for 4 days, followed by cell
counting plotted as % DMSO treated control. Error bars indicate ±SD. ***p = 0.001 and *p < 0.05.
See also Figure S3.Lapatinib-Induced c-Myc Expression Is Critical for
Reducing Sensitivity of Breast Cancer Cells to Lapatinib
To determine whether lapatinib-induced c-Myc is crucial for
reducing sensitivity to lapatinib, or is simply a biomarker respon-
sive to the inhibition of the HER2/AKT pathway, we transduced
a doxycycline-inducible c-Myc shRNA into BT474 cells. Western
blotting showed that in control cells doxycycline led to effective
knockdown of c-Myc (Figure 3A, lane 2), but did not affect cell
growth (Figure 3B, column 2). Notably, doxycycline-induced
knockdown of c-Myc precluded full c-Myc induction by lapatinib
at 25 nM concentration (Figure 3A, lane 4), and significantly
reduced cell number (Figure 3B, column 4). Consistently,
increasing the concentration of lapatinib to 50 nM reduced cell
number compared to control (Figure 3B), and notably, doxycy-
cline-inducedc-Mycknockdowneven further reducedcell growth
(Figure 3B, column 6). Together, these results indicate that induc-476 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.ible c-Myc knockdown synergized with lapatinib to suppress the
growth of cancer cells, increasing sensitivity to lapatinib.
BRD4 is a chromatin-associating protein that can bind acety-
lated histones via its BET domain to upregulate gene transcrip-
tion (Dey et al., 2003), and recently developed BRD4 inhibitors
suppress leukemia and sarcoma partly by suppressing c-Myc
expression (Dawson et al., 2011; Filippakopoulos et al., 2010).
We found that IBET151 (IBET hereafter), a small molecule inhib-
itor of BRD4, abolished lapatinib-induced upregulation of c-Myc
mRNA in BT474 cells (Figure 3C). Similar results were also
observed in MDA-MB-361 cells after co-treatment with AKTi
and IBET (Figure S3A). Consistently, western blotting showed
that IBET almost abolished lapatinib-induced expression of c-
Myc at the protein level (Figure 3D). Moreover, IBET also reduced
lapatinib-induced Bcl2 expression and increased PARP cleav-
age, an indicator of apoptosis, but had little effect on expression
of Bim (Figure 3D). Consistently, IBET synergized with lapatinib
to suppress the breast cancer cells (Figure S3B).
Because lapatinib-mediated inhibition of HER2 represses a
cascade of downstream protein kinases including PI3K and
AKT, which phosphorylates and thus inhibits FOXO transcription
factors by excluding their nuclear distribution (van der Horst and
Burgering, 2007), we examined whether IBET has an impact on
expression of FOXO1 and its cellular distribution in BT474 cells.
As expected, lapatinib increased localization of FOXO1 in the nu-
cleus, the active fraction of FOXO1. However, IBET treatment did
not change the expression or cellular distribution of FOXO1
(Figure S3C).
We ectopically expressed c-Myc in BT474 cells, and then
determined whether ectopically expressed c-Myc reduces sensi-
tivity to lapatinib. Western blot showed that transduction of the
cells with the c-Myc-expressing recombinant viruses moderately
over-expressed c-Myc (Figure 3E). Lapatinib-induced c-Myc
expression, consistently, was completely blocked by IBET in vec-
tor-transduced control cells (Figure 3F, lane 2), and correlated
well with reduction of cell growth (Figure 3G, column 2). Notably,
IBET failed to completely suppress c-Myc expression in the cells
ectopically transduced with c-Myc (Figure 3F, lane 4 versus 2),
likely because the viral promoter-driven expression of the ectopic
c-Myc was independent of BRD4. In agreement, the IBET-resis-
tant expression of ectopic c-Myc was closely correlated with the
reduced sensitivity of the cells to potent suppression by a combi-
nation of lapatinib and IBET (Figure 3G column 4 versus 2).
To control for potential off-target effects of the c-Myc shRNA,
we generated a c-Myc expressing vector that contains silent mu-
tations in the sequence that is targeted by the c-Myc shRNA. Our
results showed that doxycycline modestly reduced the c-Myc
protein in control cells, as expected (Figure S3D, lanes 1 and
2, bottom). Lapatinib induced c-Myc expression in vector control
cells as expected (lane 3) and the expression of endogenous c-
Myc was reduced by doxycycline-induced c-Myc shRNA (lane
4), which correlated with lapatinib-induced reduction of the num-
ber of the lapatinib-treated cells (graph above lane 4).
Consistently, ectopic expression of wild-type c-Myc led to
increased level of c-Myc (Figure S3D lane 5), and induction of
c-Myc shRNA by doxycycline resulted in suppression of c-Myc
expression (lane 6), consistent with the reduction of the number
of the lapatinib-treated cells (graph bar above lane 6). Likewise,
ectopic expression of c-Myc with the silence mutation in the
shRNA target site also led to increased c-Myc protein expression
(lane 7). Notably, doxycycline-induced c-Myc shRNA failed to
substantially suppress c-Myc expression, consistent with the
resistance of the cells to lapatinib-induced suppression of cell
growth (graph bar above lane 8). Collectively, these results
strongly suggest that the shRNA-mediated suppression of c-
Myc, but not the off-target effects of c-Myc shRNA, cooperates
with lapatinib to suppress the breast cancer cells.
Together, the above four lines of evidence strongly suggest
the lapatinib-induced c-Myc is crucial for reducing sensitivity
of the cancer cells to lapatinib.
A c-Myc Epigenetic Inhibitor Synergizes with Lapatinib
to Suppress Breast Cancer Cells
Consistently, IBET synergized with lapatinib to suppress cell
growth of BT474 cells, with a combination index (CI) of 0.61 (Fig-Cure 4A), where a CI <1 indicates a synergy (Chou, 2010). IBET
also synergized with AKTi to suppress growth of MDA-MB-361
(Figure 4B) and MCF-HER2 cells (Figure S4A). To assess
whether the FOXO/c-Myc axis affects the activity of an AKT in-
hibitor in PIK3CAmutant breast cancer cells without concurrent
HER2 amplification, such as T47D cells (Aksamitiene et al.,
2010), we treated T47D cells with AKTi and/or IBET, and found
that indeed treatment of T47D cells with AKTi alone had little ef-
fect on growth of the cancer cells up to 500 nM (Figure S4B,
right). Notably, IBET substantially sensitized the single agent
AKTi-induced suppression of the growth of T47D cells (Fig-
ure S4B, left). Consistently, AKTi induced c-Myc expression,
which was suppressed by IBET (data not shown). These findings
are consistent with the notion that lapatinib/AKTi-induced c-Myc
is crucial for reducing the cancer cell sensitivity to lapatinib/AKTi,
but suppression of c-Myc by IBET increased the sensitivity.
We also treated HER2+ UACC812 cells and found that lapati-
nib-induced c-Myc expression was effectively suppressed by
treatment with IBET (Figure S4C), which enhanced lapatinib-
induced suppression of the cell growth (Figure S4D). Collectively,
these results strongly suggest that IBET or knockdown of IBET
target synergizes with lapatinib to suppress the breast cancer
cells and that lapatinib-induced c-Myc expression dampens
sensitivity of the HER2+ breast cancer cells to lapatinib.
Furthermore, colony formation assay showed that IBET also
synergized with lapatinib to suppress BT474 cells (Figure 4C),
and with AKTi to suppress MBA-MB-361 cells (Figure 4D). Alto-
gether, these results indicate that IBET-mediated suppression of
c-Myc, at least partly, contributes to increasing sensitivity, or
reducing resistance, to lapatinib. We also found that knockdown
of BRD4, a target of IBET, also abolished lapatinib-induced
expression of c-Myc (Figure 4E) and also reduced cell growth.
Notably BRD4 knockdown further reduced the lapatinib-induced
suppression of cell growth (Figure 4F).
FOXOs Mediate Lapatinib-Induced Expression of c-Myc
While we have shown that lapatinib or AKTi-induced c-Myc is
crucial for reducing lapatinib sensitivity, little is known as to
how lapatinib induces c-Myc expression. We noticed that lapa-
tinib not only markedly increased expression of c-Myc, but
also dramatically increased expression of total FOXO1 (Fig-
ure S2C) and reduced FOXO1 phosphorylation (Figure 2B).
This observation of close association of FOXO1 and c-Myc regu-
lation prompted us to investigate whether FOXOs affect c-Myc
expression. However, a link between FOXO activation and c-
Myc expression is paradoxical and unexpected, because nor-
mally FOXOs are tumor-suppressing factors while c-Myc is a
bona fide proto-oncogene, and in fact FOXOs and c-Myc mutu-
ally antagonize each other in various settings (Bouchard et al.,
2007; Peck et al., 2013).
Notably, when we treated BT474 cells with a small molecule
FOXO1 inhibitor that binds to unphosphorylated FOXO1 and
decreases FOXO1 transactivation (Nagashima et al., 2010),
lapatinib-induced expression of c-Myc and Bcl2 was markedly
reduced at both the mRNA and protein levels (Figures 5A
and S5A). We further found that FOXO1 knockdown substan-
tially reduced lapatinib-induced c-Myc expression (Figure 5B).
Knockdown of both FOXO1 and 3 moderately reduced cell
growth, but further reduced lapatinib-mediated suppression ofancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 477
Figure 4. The Impact of a c-Myc Epigenetic Inhibitor on Suppressing Lapatinib-Induced c-Myc Expression and on Synergizing with Lapatinib
to Suppress Breast Cancer Cells
(A and B) BT474 (A) or MDA-MB-361 (B) breast cancer cell line was treated with IBET alone (bottom), or its combination with increasing concentrations of la-
patinib/AKTi (top), respectively, for 5 days prior to MTS assay.
(C and D) BT474 (C) or MDA-MB-361 (D) cells (106) were seeded in 60 mm dishes and treated with DMSO, 100 nM lapatinib/50 nM AKTi, or 500 nM IBET alone or
combination of lapatinib/AKTi with IBET for 7 days, followed by crystal violet staining.
(E and F) BT474 cells transduced either with scrambled vector or BRD4 shRNA lentiviruses, followed by treatmentwith either DMSOor lapatinib for 4 days, prior to
measuring c-Myc expression using qRT-PCR (E) or counting viable cells (F). Error bars indicate ±SD.
See also Figure S4.the cell growth (Figure 5C). Consistently, FOXO1/3 knockdown
also potently blocked lapatinib-induced c-Myc expression at
both the mRNA and protein level (Figures 5D and 5E). Similarly,
FOXO1/3 knockdown also blocked lapatinib-induced expres-
sion of Bcl2 (Figures S5B and 5E).
To extend our findings to additional HER2 amplified or
PIK3CA mutated cell lines, we knocked down expression of
FOXO1/3 in MDA-MB-361 cells, and found that the FOXO
knockdown decreased ATKi-induced c-Myc expression (Fig-
ure S5C). Consistently, knockdown of FOXOs in HER2+
UACC812 cells modestly decreased lapatinib-induced expres-
sion of c-Myc (Figure S5D). Moreover, the FOXO inhibitor
(FOXOi) also reduced lapatinib-induced c-Myc expression (Fig-
ure S5E). Together, these results demonstrate that FOXO1/3
are required for lapatinib-induced c-Myc expression and their
knockdown sensitizes the cancer cells to lapatinib-induced
suppression of cell growth.
MLL2 and Its Partners Are Crucial for Reducing
Sensitivity to Lapatinib
We showed that MLL2 was crucial for expression of c-Myc, but
not Bclxl, and we thus determined whether MLL2 is also crucial478 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.for lapatinib-induced c-Myc expression. We found that MLL2
knockdown in BT474 cells reduced cell growth, and lapatinib
further reduced the growth of MLL2 knockdown cells (Figure 5F).
Consistently, MLL2 knockdown also markedly suppressed lapa-
tinib-induced upregulation of the c-Myc mRNA (Figure 5G). It is
currently unclear what precise proportion of the effects of
MLL2 knockdown on cell viability is due to loss of c-Myc expres-
sion. Moreover, knockdown of GCN5, a histone acetyltransfer-
ase, also suppressed lapatinib-induced expression of c-Myc
(Figure S5F). These findings suggest that epigenetic regulator
MLL2, its partners, and GCN5 play a crucial role in lapatinib-
induced expression of c-Myc and reduction of sensitivity to lapa-
tinib treatment.
Lapatinib Induces Direct Binding of FOXOs to the c-Myc
Promoter to Promote c-Myc Expression
We explored whether FOXOs directly bind the c-Myc locus.
Notably, a survey of DNA sequence in the c-Myc locus revealed
a consensus ‘‘TGTTTAC’’ sequence of the FOXO binding
element (FBE) in the c-Myc promoter that is conserved across
multiple species (Figure 6A). Chromatin immunoprecipitation
(ChIP) assay indicated that lapatinib induced binding of
Figure 5. The Role of FOXOs and MLL2 in Mediating Lapatinib-Induced Expression of c-Myc
(A) BT474 cells were treated with FOXO1 inhibitor, AS1842856, and/or lapatinib for 4 days, and subjected to analysis for c-Myc mRNA by qRT-PCR or the protein
level with western blot.
(B) The cells were transduced with control or FOXO1 shRNAs, and the resulting stable cells were subjected to analysis of mRNAs for FOXO1 or c-Myc.
(C–E) The control or FOXO1/3 KD cells were treated with DMSO or lapatinib for 4 days, followed by analyzing the number of viable cells (C), c-Myc expression (D),
or protein levels of c-Myc, Bcl2, and FOXOs (E).
(F and G) Control or MLL2 shRNA-transduced BT474 cells were treated with either DMSO or lapatinib, followed by cell counting (F) or qRT-PCR for c-Myc
expression (G). Error bars indicate ±SD.
See also Figure S5.FOXO1/3 to the c-Myc promoter in BT474 cells (Figure 6B). To
further determine whether the FOXO binding site is crucial for
FOXO-mediated gene transcription, we constructed a lucif-
erase reporter driven by either the wild-type FBE from the c-
Myc promoter or its mutant form, and transfected them into
BT474 cells, followed by lapatinib treatment and detection of
the mRNA of the reporter gene. We found that lapatinib
increased expression of the reporter driven by the wild-type
FBE 4-fold, but not by the mutant FBE (Figure 6C), indicating
that the FBE in the c-Myc promoter is required for FOXO-medi-
ated expression of c-Myc.
Importantly, lapatinib induced the recruitment of MLL2 to
the c-Myc promoter (Figure 6D) and increased detection of
GCN5 (Figure 6E) and histone H3 lysine 4 trimethylation
(H3K4m3) and histone H3 acetylation (Figure 6F), both his-Ctone markers for active gene transcription, at the c-Myc
locus.
ChIP assay showed that FOXOi did not affect FOXO binding
to the c-Myc promoter (data not shown), but reduced lapati-
nib-induced recruitment of MLL2 and RNA polymerase II,
H3K4m3, and histone acetylation at the c-Myc locus (Figures
6G and S6A). Similarly, FOXOi also reduced the recruitment
of MLL2 to the Bcl2 locus (Figure S6B) and the level of
H3K4m3 mark and histone acetylation at the locus, while not
affecting the level of total histone H3 (Figure S6C). We also
found BRD4, at the c-Myc promoter in cells treated with lapa-
tinib, but IBET potently inhibited binding of BRD4 to the c-Myc
locus (Figure 6H), while not affecting FOXO1 translocation to
the nucleus (Figure S3C, lane 4). Consistently, binding of
FOXO1/3 or MLL2 to the c-Myc promoter was also inducedancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 479
Figure 6. The Role of Lapatinib in Regulating Binding of FOXOs, Recruitment of the Histone Modifiers, and Histone Modifications at the c-
Myc Locus
(A) A conserved FOXO binding element (FBE) in the promoter of the c-Myc gene in various species.
(B) ChIP analysis for binding of FOXO1 and FOXO3 to the c-Myc promoter in BT474 cells upon daily lapatinib treatment for 3 days, followed by 18 hr fresh treatment.
(C) BT474 cells transfectedwith a luciferase reporter driven by either the wild-type FBE or themutant form (top), followed by treatment with lapatinib for 18 hr prior
to qRT-PCR analysis for the reporter expression.
(D–F) The control and lapatinib-treated cells were subjected to ChIP assay for detecting binding of MLL2 (D) and GCN5 (E) as well as H3K4m3 and histone
acetylation (F) at the c-Myc locus.
(G) BT474 cells were treated with FOXOi and/or lapatinib for 4 days, followed by ChIP assay for detecting MLL2 binding (left) or H3K4m3 and histone acetylation
(right) at the c-Myc locus.
(H) The cells were treated with lapatinib and/or IBET for 4 days, collected 18 hr after last treatment followed by ChIP assay to detect BRD4 binding to the c-Myc
locus. Error bars indicate ±SD.
See also Figure S6.by lapatinib in HER2+ UACC812 cells as shown by ChIP assay
(Figure S6D). Collectively, these results indicate that lapatinib
induces FOXO binding to the c-Myc promoter, enhances the
recruitment of epigenetic regulators including MLL2 to the c-
Myc promoter, and increases histone acetylation and recruit-
ment of BRD4 at the c-Myc locus. This coordinated action
may lead to increased expression of target genes such as
c-Myc, and at least partly results in reduced sensitivity to lapa-
tinib. Inhibition of BRD4 binding reduces transcription of c-
Myc but increases the sensitivity to lapatinib in the breast
cancer cells, and synergizes with lapatinib to suppress the
growth of breast cancer cells.480 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.Lapatinib and IBET Synergistically Suppress HER2+
Cancer in Xenograft Models
To determine whether a combination of lapatinib and IBET syn-
ergizes to suppress the HER2+ breast cancer in xenograft
models, we first induced tumors in immunodeficient mice with
transplantation of BT474 cells. When the tumors were formed
visibly, we started to treat themicewith control vehicle, lapatinib,
IBET, or a combination of lapatinib and IBET. At the end of the
observation, the tumors were collected, and used for making
RNA or for immunohistochemistry analysis.
We found that treatment of the mice with either lapatinib or
IBET alone moderately slowed tumor growth (Figure 7A).
Figure 7. The Impact of a Combination of Lapatinib and IBET on Suppressing HER2+ Cancer in Xenograft Models
(A) Nudemice were transplanted with 103 106 BT474 cells, 16 days after transplantation, when the tumors were established, the mice with tumor size >150mm3
(n = 6 per group) were treated with control saline, or lapatinib (25mg/kg on alternate days by oral gavage) and/or IBET (15mg/kg intraperitoneal injection daily), for
the indicated number of days. The size of the tumors was measured with a Vernier caliber every 3 days. Error bars indicate ±SEM. *p = 0.0113; **p = 0.0077.
(B) Tumors from four mice from each group were collected 16 hr after last treatment, at the end of study and used to isolate RNAs, which were used to detect the
mRNA levels of c-Myc or Bcl2. Error bars indicate ±SD.
(C) Representative hematoxylin and eosin staining of the transplanted tumors from each of the four groups. The measurement bar denotes 50 mM.
(D) Immunofluorescent staining for c-Myc from tumors treated with the indicated conditions. The bar denotes 200 mM.
See also Figure S7.Notably, a combination of lapatinib and IBET significantly re-
duced growth of the tumor (Figure 7A). The body weight of
the mice in four groups of the mice was not substantially
changed (data not shown). Consistently, lapatinib also induced
expression of c-Myc, but treatment with IBET blocked c-Myc
and Bcl2 induction in the collected tumor samples, as shown
by qRT-PCR (Figure 7B). While the lapatinib and IBET combina-
tion did not show marked reduction in the tumors in size (Fig-
ure 7A), hematoxylin and eosin staining of the tumor tissue
showed that the number of cells was substantially reduced in
the tumor treated with the combination, filled with fibrosis-like
tissue (Figure 7C). Consistently, immunofluorescent staining
showed that c-Myc was induced in the tumor cells treated with
lapatinib, but the induction was quenched by IBET treatment
(Figure 7D).
We also performed a similar tumor xenograft experiment using
another HER2-amplified cell line, UACC812. Consistently, we
found that treatment of the mice bearing UACC812 cell-derivedCtumors with either lapatinib or IBET alone only moderately sup-
pressed the tumor growth (Figure S7A). Notably, a combination
of lapatinib and IBET led to significant suppression of the tumor
burden (Figure S7A): lapatinib upregulated expression of c-Myc,
as shown by immunohistochemistry staining, but IBET treatment
substantially reduced lapatinib induced c-Myc expression (Fig-
ure S7B). Together, these in vivo studies strongly suggest that
targeting the MLL2/FOXO/BRD4/c-Myc axis may represent a
great avenue to increase sensitivity and reduce resistance to in-
hibitors of the HER2/AKT pathway, leading to marked improve-
ment of therapy.
DISCUSSION
We took an unbiased shRNA screening approach and identified
multiple components from the MLL2 complex that are crucial for
the maintenance of HER2+ BT474 breast cancer cells. By inves-
tigating the potential role of the MLL2 complex and associatingancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 481
Figure 8. A Model Summarizing the Epige-
netically Regulated MLL2/FOXO/BRD4/c-
Myc- Axis in Reducing the Sensitivity of
the HER2+ Breast Cancer Cells to Lapatinib,
and the Synergy of Lapatinib and IBET in
Suppressing HER2+ Breast Cancerfactors in response of the breast cancer cells to inhibitors of the
HER2/AKT pathway, we uncovered an important link between
the epigenetic MLL2 complex/FOXO/c-Myc axis and reducing
sensitivity of HER2+ breast cancer cells to the HER2 inhibitor, la-
patinib. These findings are crucial and significant in the following
aspects: First, because the HER2/PI3K/AKT pathway is often
upregulated or activated in a broad spectrum of cancers (Court-
ney et al., 2010), and targeting the kinases of this pathway is
promising yet thus far has only yielded limited success due to
quick development of reduced sensitivity (Chandarlapaty et al.,
2011; Muranen et al., 2012), our findings of an intrinsic and
epigenetic pathway that partially accounts for the reduced sensi-
tivity unravels multiple epigenetic components that could be tar-
geted to improve therapy.
Second, because FOXOs and c-Myc are normally considered
tumor suppressor and oncogene, respectively (Bouchard et al.,
2007; Peck et al., 2013), our findings that FOXOs positively regu-
late c-Myc to reduce sensitivity of the cancer cells to lapatinib or
AKTi provide insights into how tumor suppressing FOXOs act in
concert with c-Myc to reduce the sensitivity to lapatinib in the
breast cancer cells. These findings suggest means to sensitize
the HER2+ or PI3K/AKT pathway-activated breast cancer cells
to the inhibitors to improve therapy.
Third, mechanistically, we found that the MLL2/FOXO axis
regulates transcription of c-Myc mRNA in concert with a
cascade of other chromatin modifying or associating proteins
such as GCN5 and BRD4. Finally, as proof of principle based
on these mechanistic findings (Figure 8), we found that an epige-
netic inhibitor against BRD4, IBET, synergizes with lapatinib at
lower concentrations to suppress HER2+ cancer in vitro and
in vivo. It is conceivable that multiple components in this
pathway can also be similarly targeted in combination with the
HER2/PI3K/AKT inhibitors to cause synthetic lethality in other
types of cancer cells and improve therapy.
We uncovered that multiple epigenetic regulators, including
components from the MLL2 epigenetic complex such as482 Cancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc.MLL2, WDR5, RBBP5, and GCN5 are
crucial for growth of BT474 cells. These
proteins upregulate expression of mul-
tiple pro-proliferative/survival targets,
including c-Myc and Bcl2. In contrast,
other methyltransferases such as MLL3
and MLL4 did not affect growth of the
breast cancer cells, indicating a specific
role for MLL2 in regulating these target
genes in breast cancer cells. Although
loss-of-function mutations in MLL2 lead
to inherited Kabuki syndrome and follic-
ular lymphoma (Makrythanasis et al.,
2013; Morin et al., 2011), a recent report
suggests that MLL2 plays an important
role in maintenance of HER2+ colon cancer cells via upregulating
ITGB4 and NRG1 (Guo et al., 2012). Thus, the function of MLL2
and its related proteins in regulating cancer cells may be cell-
type or signaling pathway-specific. It is also possible that other
epigenetic regulators, although not the components of the
MLL2 complex (such as GCN5, BPTF, and BRDs), are also
involved in the process because they are also crucial for growth
of the HER2+ cancer cells. These findings pave the way to inves-
tigate whether this epigenetic pathway is also crucial for regu-
lating the cancer cell sensitivity to other inhibitors of the HER2/
PI3K/AKT pathway.
Whereas the HER2/PI3K/AKT pathway is often upregulated or
activated in multiple types of cancers (Courtney et al., 2010), tar-
geted inhibition of this pathway has only met limited success due
to reduced sensitivity via various mechanisms including upregu-
lation of RTKs (Chandarlapaty et al., 2011; Garrett et al., 2011;
Muranen et al., 2012). Our results suggest that HER2/AKT inhib-
itor-induced FOXO/c-Myc is an important axis that reduces
sensitivity to the inhibitors, as these inhibitors induced c-Myc
expression in multiple HER2+ or PIK3CA-mutated human breast
cancer cell lines, and downregulating c-Myc expression syner-
gizes with lapatinib to suppress HER2+ breast cancer cells.
Our data also suggest that temporally in the early phase of
treatment, lapatinib suppressed cell growth and survival, likely
partly via upregulating expression of Bim and CDKI like p27kip
by lapatinib-activated FOXOs (Greer and Brunet, 2005). In the
late phase of treatment after 3–6 days, on daily treatment with la-
patinib, expression of c-Myc is further upregulated by marked
upregulation of FOXOs in concert with other epigenetic regula-
tors including the MLL2 complex, thereby reducing sensitivity
to lapatinib. This may also partly explain that c-Myc is important
for tumor dormancy after treatment (Bellovin et al., 2013), as la-
patinib may lead to cell killing in early treatment but its chronic
effect on c-Myc induction may facilitate development of tumor
dormancy. Other pathways including estrogen receptor sig-
naling and lapatinib-induced RTKs are also likely involved in
regulating or crosstalk with the FOXO/c-Myc axis in response
to HER2 inhibition. However, we cannot rule out the possibility
that the synergistic effect of lapatinib and IBET also involves
additional factors beyond c-Myc. The lapatinib-induced c-Myc
expression reduces the drug sensitivity likely partly via multiple
pathways including regulating ribosomal biogenesis, as well as
reprogramming the cancer metabolic pathways and promoting
survival (van Riggelen et al., 2010).
It is noteworthy that inhibition of the HER2/AKT pathway inev-
itably leads to activation of FOXOs, which are normally tumor-
suppressing factors (Zhang et al., 2011), by reducing FOXO
phosphorylation. FOXOs antagonize c-Myc in renal cell carci-
noma RCC4 cells, possibly by increasing the expression of
miR-145 (Gan et al., 2010). Thus, our findings define an intrinsic
adaptive pathway via FOXO/c-Myc to reduce drug sensitivity.
Our results show that the normally mutually antagonistic
FOXOs and c-Myc cooperate to reduce sensitivity to lapatinib
in breast cancer cells with enhanced HER2/PI3K signaling.
Whereas constitutively high expression or amplification of c-
Myc in a subset of breast cancer cells results in resistance to
PI3K inhibitor (Ilic et al., 2011), our findings indicate that in
the breast cancer cells with enhanced HER2/PI3K signaling
the basal level of c-Myc is not crucial for maintenance of the
cells. Rather, lapatinib-induced c-Myc expression mediated by
MLL2/FOXO is responsible for reducing sensitivity to lapatinib.
These findings raise an attractive possibility that inhibiting
MLL2/FOXOs/c-Myc axis synergizes with the HER2/PI3K/AKT
inhibitors to suppress HER2+ breast cancer and likely other
PI3K/AKT-activated cancers as well. Conceivably, preemptively
targeting this common and intrinsic pathway that reduces the
drug sensitivity may be a good strategy to improve the therapeu-
tic efficacy of the HER2/AKT/PI3K inhibitors.
Our findings suggest the following model: First, lapatinib or
PI3K/AKT inhibitor suppresses the kinases, leading to activation
of FOXOs, which in turn translocate into the nucleus and recruits
MLL2 and GCN5 to their target gene, c-Myc, to add active his-
tone marks, including H3K4m3 and histone acetylation. The
modified histones can further recruit proteins such as BPTF, an
H3K4m3binding protein, and BRD4, an acetylated histone-bind-
ing protein, to the target genes, leading to increased gene
transcription (Figure 8). MLL and GCN5 complexes can both
be recruited to Myc gene to epigenetically upregulate its expres-
sion (Choi and Boss, 2012). It is likely that FOXO and/or FOXO-
mediated MLL2 is also conducive to recruitment of GCN5 and
histone acetylation at the locus. While extensive work was
carried out to unravel the epigenetic pathway in regulating the
sensitivity of HER2+ breast cancer cells to the HER2 and AKT in-
hibitors, the detailed mechanisms governing their crosstalk of
the pathway’s components remain to be further investigated.
Nevertheless, these players are crucial for reducing the sensi-
tivity of the cancer cells to lapatinib because knockdown of
FOXO1/3, MLL2, and BRD4 potentiated lapatinib-induced sup-
pression of the cancer cells.
IBET was not very effective as a single agent in inhibiting
HER2+ breast cancer cells with the dose used in our study.
Rather, a combination of lapatinib with IBET synergistically sup-
pressed HER2+ breast cancer cells in cell culture more effec-
tively at lower concentrations of lapatinib/AKTi and in a mouse
model. This combination blocks lapatinib-induced upregulationCof c-Myc, and it is conceivable that IBET can also inhibit expres-
sion of other genes besides c-Myc that are induced by lapatinib
such as HER3. As such, it is possible that inhibitors of epigenetic
regulators involved in the MLL2/FOXO/c-Myc axis, such as
MLL2, WDR5, BPTF, and GCN5 could also be targeted to
improve HER2/PI3K/AKT inhibitor-mediated therapy. While a
combination of lapatinib and IBET also suppressed growth of
UACC812 cell-derived tumors more effectively, the combination
did not eliminate the tumor. It is possible that the cancer cells
were influenced by additional microenvironmental factors during
the treatment. Alternatively, it is also possible that better dosing
and timing are needed to further increase the efficacy. These re-
sults also indicate that multiple components in the epigenetic
MLL2/FOXO axis could be preemptively or simultaneously tar-
geted with the HER2/PI3K/AKT inhibitors to cause synthetic
lethality of the HER2+ breast cancers. Other types of tumors
with the constitutively active RTK/PI3K/AKT pathway may also
be susceptible to this strategy.
EXPERIMENTAL PROCEDURES
Cell Lines, Cell Culture, Drug Treatment, and Plasmids
TheUACC812 cell line, which containsHER2 amplification,MDA-MB-361, and
T47D cell lines (which harbor a PIK3CA active mutation; Aksamitiene et al.,
2010), were purchased from ATCC. BT-474 cell line was a gift from Dr. Lewis
Chodosh; MCF-HER2 and MCF-Neo cell lines were gifts from Dr. Mien-Chi
Hung. To generate a cell line with conditional expression of c-Myc shRNA,
shRNA oligonucleotides for c-Myc were cloned into pLKO-tet-on vector
from Addgene. BT474 cells were transduced with either scramble or shRNA
targeted against c-Myc mRNA. Cells were selected with puromycin. Wild-
type c-Myc was cloned in MSCV-neo vector from Addgene. To obtain
c-Myc impervious to shRNA knockdown site directed mutagenesis of this
plasmid was performed to change 50-CAGCAAC to 50-ATCGAAT using a kit
from Stratagene. All cell lines were cultured in DMEM with 10% FBS and
1% penicillin/streptomycin and maintained at 37C and 5% CO2.
Immunoblotting
Lysates from cells in culture were prepared by washing twice in cold PBS fol-
lowed by lysis with either SDS-lysis buffer (20 mM Tris-HCl [pH 8], 100 mM
NaCl, 1% SDS) or RIPA-lysis buffer supplemented with protease and phos-
phatase inhibitors. For lysis in SDS, lysates were boiled for 5 min followed
by brief sonication. Lysates were cleared by centrifugation at 14,000 3 g
(10 min) and the supernatant was collected. Protein concentration of each
sample was determined using the BCA kit (Pierce) per manufacturer’s instruc-
tions. Proteins (25 or 50 mg) were loaded onto 4%–10% SDS-PAGE minigels
for immunoblotting.
qRT-PCR
Total RNAwas extracted from cultured cells using Trizol as previously reported
(Thiel et al., 2010). RNA (1 mg) was used to make cDNA. Real-time PCR was
performed using 7500 fast real time PCR System. SDS software was used
for data analysis. Sequence of the probes used can be found in the Supple-
mental Experimental Procedures.
Breast Cancer Xenograft in Mice
All laboratory mice were maintained on a 12 hr light-dark cycle in the animal
facility at the University of Pennsylvania. All experiments on mice in our
research protocol were approved by Institutional Animal Care and Use Com-
mittee of the University of Pennsylvania and were performed in accordance
with relevant institutional and national guidelines and regulations. 6- to 8-
week-old nu/nu athymic female mice were obtained from NCI-Frederick
Cancer Center. Mice were implanted with 0.72 mg sustained-release estradiol
pellets (Innovative Research of America) 3 days before 10 3 106 BT474 or
UACC812 cells with Matrigel (1:1) were injected into the right flanks of the
mice. Mice with tumor size 100 mm3 were randomized into four groupsancer Cell 28, 472–485, October 12, 2015 ª2015 Elsevier Inc. 483
and treated with vehicle, lapatinib, IBET or lapatinib + IBET with the indicated
doses. Tumor dimensions were measured with Vernier calipers and tumor vol-
ume was calculated as 1/2 larger diameter 3 (smaller diameter)2.
Statistical Analysis
Microsoft Excel and GraphPad Prism software were used for statistical anal-
ysis. Student’s t test and Annova were used to determine the significance of
the results.
Additional procedures can be found in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.09.005.
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